48 Macrophage Activation Syndrome. In: Textbook of Pediatric Rheumatology. Elsevier; 2027:669-677.
Current State of Allogeneic Hematopoietic Cell Transplantation for Still's Disease: A Collaborative Perspective from Attendees of the Systemic Juvenile Idiopathic Arthritis Foundation NextGen Conference. Arthritis Care and Research. 2026.
Tear-based biomarker trajectories associated with uveitis in juvenile idiopathic arthritis: a multicenter prospective study. Arthritis Care and Research. 2026.
Cumulative Social Disadvantage and Disease Activity in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study. Arthritis Care and Research. 2026; 78(10):1552-1563.
Dr. Eloseily et al reply. Journal of Rheumatology. 2026; 53(10):1169.
Comparing Real-World Evidence With Clinical Trials in Juvenile Idiopathic Arthritis. Pharmacoepidemiology and Drug Safety. 2026; 35(10):e70492.
Treatment Approaches to Macrophage Activation Syndrome in Real Life and Priorities for Future Research: Results From the International METAPHOR Project. Arthritis & Rheumatology. 2026.
Spatial transcriptomics reveals distinct phenotype of proliferating and interferon-activated T lymphocytes in macrophage activation syndrome driven liver inflammation in systemic juvenile idiopathic arthritis. Arthritis Research & Therapy. 2026.
AMETHYST: A Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid-Refractory Macrophage Activation Syndrome Complicating Still's Disease. Arthritis & Rheumatology. 2026.
Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease Cohort. Arthritis Care and Research. 2026; 78(8):1036-1048.
Distinct cytokine and chemokine alterations in bronchoalveolar fluid from patients with systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD). Arthritis Research & Therapy. 2026; 28(1).
Validation of the Pediatric Arthritis Ultrasound Scoring System for the Elbow, Wrist, and Finger Joints in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2026; 78(7):905-913.
Hepatic Manifestations in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome. Journal of Rheumatology. 2026; 53(6):669-678.
Challenging traditional classifications: Gene penetrance in genetically transitional disease. Genes and Diseases. 2026; 102334.
Speaking the same language: international cross-validation of emerging biomarkers for juvenile idiopathic arthritis and Still's Disease. Pediatric Rheumatology. 2026; 24(1).
Pathogenic and genetic landscape of Still's disease across ages, with new insights into age-related IL-18 patterns. Arthritis Research & Therapy. 2026; 28(1).
Reliability and Construct Validity of the Physician's Global Assessment of Lung Disease in Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. ACR Open Rheumatology. 2026; 8(3):e90006.
Evaluation of steroids for acute COVID in the prevention of long COVID in children: An EHR and pediatric cohort study from the RECOVER Initiative. PLoS ONE. 2026; 21(6):e0350888.
Update on new autoinflammatory disorders from the 2024 Pediatric Rheumatology European Society Congress. Pediatric Rheumatology. 2025; 23(1):107.
Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry. Pediatric Rheumatology. 2025; 23(1):105.
Three-Year Outcomes and Latent Class Trajectory Analysis of the Childhood Arthritis and Rheumatology Research Alliance Polyarticular JIA Consensus Treatment Plans Study. Arthritis & Rheumatology. 2025; 77(10):1433-1441.
Juvenile Psoriatic Arthritis Inception Cohort in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Characteristics and Early Disease Outcomes. Journal of Rheumatology. 2025; 52(10):1013-1020.
Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain. Lupus Science and Medicine. 2025; 12(2).
Disease activity at two consecutive registry visits and subsequent medication escalation for patients with juvenile idiopathic arthritis in the CARRA registry. Pediatric Rheumatology. 2025; 23(1):77.
Utility of patient-reported outcomes for pulmonary symptoms and sleep disturbance and impairment in children with systemic juvenile idiopathic arthritis. Pediatric Rheumatology. 2025; 23(1):74.
Juvenile Idiopathic Arthritis. New England Journal of Medicine. 2025; 393(2):162-174.
Genetic Inflammatory Diseases with Ocular Involvement. In: Genetic Diseases of the Eye. Oxford University Press (OUP); 2025:1070-1091.
Candidate Tear-Based Uveitis Biomarkers in Children with JIA Based on Arthritis Activity and Topical Corticosteroid Use. Ocular Immunology and Inflammation. 2025; 33(4):603-612.
Clinical, Immunologic, and Genetic Characteristics in Patients With Syndrome of Undifferentiated Recurrent Fevers. Arthritis & Rheumatology. 2025; 77(5):596-605.
Lung Disease in Systemic Juvenile Idiopathic Arthritis: An Atypical Path to Diagnosis. American Journal of Respiratory and Critical Care Medicine. 2025; 211(Supplement_1):a7865-a7865.
Experience with T Cell–Depleted Allogeneic HSCT for Refractory sJIA Associated with Lung Disease. Journal of Human Immunity. 2025; 1(CIS2025).
Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study. The Lancet Rheumatology. 2025; 7(4):e243-e251.
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project. Rheumatology. 2025; 64(1):32-44.
Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry Study. Arthritis Care and Research. 2025; 77(1):38-49.
Effect of an Electronic Pill Bottle on Hydroxychloroquine Adherence in Pediatric Lupus: Results of a Novel Direct-to-Family Pilot Trial. ACR Open Rheumatology. 2025; 7(1):e11780.
Multidisciplinary approach to treating complex immune dysregulation disorders: an adaptive model for institutional implementation. Frontiers in Immunology. 2025; 16:1519955.
Severity of acute SARS-CoV-2 infection and risk of new-onset autoimmune disease: A RECOVER initiative study in nationwide U.S. cohorts. PLoS ONE. 2025; 20(6):e0324513.
Treatment and Visual Outcomes in Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy: A Cohort Study. Ocular Immunology and Inflammation. 2024; 32(10):2441-2448.
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned. Annals of Internal Medicine. 2024; 177(11):1547-1557.
Effects of the COVID-19 Pandemic in Patients with Systemic Autoinflammatory Diseases. An international survey. Medical Research Archives. 2024; 12(10).
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Annals of the Rheumatic Diseases. 2024; 83(11):1561-1571.
Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatric Rheumatology. 2024; 22(1):88.
Hyperferritinemia Screening to Aid Identification and Differentiation of Patients with Hyperinflammatory Disorders. Journal of Clinical Immunology. 2024; 45(1):4.
New discoveries in the genetics and genomics of systemic juvenile idiopathic arthritis. Expert Review of Clinical Immunology. 2024; 20(9):1053-1064.
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63(SI2):SI195-SI206.
Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2024; 76(8):1090-1098.
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Research & Therapy. 2024; 26(1):125.
Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. Arthritis Care and Research. 2024; 76(3):328-339.
Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology. 2024; 21(Suppl 1):86.
The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatric Rheumatology. 2024; 21(Suppl 1):87.
Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis & Rheumatology. 2024; 76(1):119-129.
Genetics of Acquired Cytokine Storm Syndromes : Secondary HLH Genetics. Advances in Experimental Medicine and Biology. 2024; 1448:103-119.
COVID-19 and Rheumatic Disease. In: Firestein Kelley S Textbook of Rheumatology 2 Volume Set. 2024:2083-2094.e5.
Spectrum of severity of multisystem inflammatory syndrome in children: an EHR-based cohort study from the RECOVER program. Scientific Reports. 2023; 13(1):21005.
Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. Journal of Clinical Investigation. 2023; 133(22).
Health Equity Implications of Missing Data Among Youths With Childhood-Onset Systemic Lupus Erythematosus: A Proof-of-Concept Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75(11):2285-2294.
Molecular Pathways in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis. Rheumatic Disease Clinics of North America. 2023; 49(4):895-911.
Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Paediatric Drugs. 2023; 25(6):649-658.
The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis & Rheumatology. 2023; 75(10):1714-1732.
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the Rheumatic Diseases. 2023; 82(10):1271-1285.
New developments related to lung complications in pediatric rheumatic disease. Current Opinion in Rheumatology. 2023; 35(5):273-277.
Comparison of disease phenotypes and mechanistic insight on causal variants in patients with DADA2. Journal of Allergy and Clinical Immunology. 2023; 152(3):771-782.
Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry. Journal of Rheumatology. 2023; 50(8):1047-1057.
Neutrophils extracellular traps formation may serve as a biomarker for disease activity in oligoarticular juvenile idiopathic arthritis: a pilot study. Arthritis Research & Therapy. 2023; 25(1):135.
Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care and Research. 2023; 75(7):1553-1562.
Efficacy and safety of emapalumab in macrophage activation syndrome. Annals of the Rheumatic Diseases. 2023; 82(6):857-865.
OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) Annals of the Rheumatic Diseases. 2023; 82:110-111.
POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL. Annals of the Rheumatic Diseases. 2023; 82:379-380.
Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis-Associated Interstitial Lung Disease. Arthritis Care and Research. 2023; 75(5):983-988.
Impact of the COVID-19 Pandemic on Early Career Investigators in Rheumatology: Recommendations to Address Challenges to Early Research Careers. Arthritis Care and Research. 2023; 75(5):947-955.
Can Multisystem Inflammatory Syndrome in Children Be Managed in the Outpatient Setting? An EHR-Based Cohort Study From the RECOVER Program. Journal of the Pediatric Infectious Diseases Society. 2023; 12(3):159-162.
Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research. 2023; 75(4):715-723.
Mouse models of systemic juvenile idiopathic arthritis and macrophage activation syndrome. Arthritis Research & Therapy. 2023; 25(1):48.
Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. Pediatric Infectious Disease Journal. 2023; 42(2):119-121.
Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry. Rheumatology. 2023; 62(2):804-814.
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Annals of the Rheumatic Diseases. 2023; 82(1):154-160.
Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis. RMD Open. 2023; 9(1).
Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2023; 41(1):186-194.
Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Journal of Rheumatology. 2023; 50(1):98-106.
Increase in pediatric recurrent fever evaluations during the first year of the COVID-19 pandemic in North America. Frontiers in Pediatrics. 2023; 11:1240242.